CSL Limited: all 268 studies

Page 1 of 3. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingNCT07648264Phase 3
• A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)RecruitingNCT07619820Phase 1
• Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)RecruitingNCT07326592Phase 4
• Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)RecruitingNCT07224360Phase 2
• Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 StudyAvailableNCT07159464
• Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)RecruitingNCT07094087Phase 3
• Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BRecruitingNCT07080905Phase 3
• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)RecruitingNCT07048262Phase 2
• A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)RecruitingNCT07001280
• Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive CrisisRecruitingNCT06699849Phase 2
• Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive SurgeryRecruitingNCT06617897Phase 3
• Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe PruritusRecruitingNCT06593392Phase 2
• An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BRecruitingNCT06008938
• Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)RecruitingNCT06003387Phase 3
• Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)Enrolling by invitationNCT05962398
• Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium LevelsRecruitingNCT05766839Phase 2
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)RecruitingNCT05485961Phase 2/3
• Hizentra® in Inflammatory Neuropathies - pHeNIx StudyRecruitingNCT04672733
• Two Dose Levels of Privigen in Pediatric CIDPRecruitingNCT03684018Phase 4
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTSTerminatedNCT06524739Phase 3Results posted
• Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on HaemodialysisCompletedNCT05885763Phase 1Results posted
• Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe PruritusCompletedNCT05885737Phase 3Results posted
• CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary AngioedemaCompletedNCT05819775Phase 3Results posted
• Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )TerminatedNCT05568888Phase 3Results posted
• Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of AgeCompletedNCT05501561Phase 2Results posted
• A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or UnprimedCompletedNCT05422326Phase 2Results posted
• Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary FibrosisCompletedNCT05130970Phase 2Results posted
• A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of AgeCompletedNCT05044195Phase 3Results posted
• Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell DiseaseCompletedNCT04817670Phase 2Results posted
• Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older AdultsCompletedNCT04782323Phase 2Results posted
• Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema AttacksCompletedNCT04739059Phase 3Results posted
• A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza VaccineCompletedNCT04669691Phase 2Results posted
• CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema AttacksCompletedNCT04656418Phase 3Results posted
• Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older AdultsCompletedNCT04576702Phase 2Results posted
• Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney DiseaseCompletedNCT04419467Phase 2Results posted
• Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)CompletedNCT04409509Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemiaCompletedNCT04364269Phase 2Results posted
• Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids AloneCompletedNCT04167514Phase 3Results posted
• Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)CompletedNCT04137224Phase 2Results posted
• Safety and Immunogenicity Study of QIVc in Healthy Pediatric SubjectsCompletedNCT04074928Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)TerminatedNCT04044690Phase 3Results posted
• Efficacy Study With QIVc in Pediatric SubjectsCompletedNCT03932682Phase 3Results posted
• Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)CompletedNCT03888066Phase 3Results posted
• Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant RecipientsTerminatedNCT03744910Phase 3Results posted
• A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)CompletedNCT03712228Phase 2Results posted
• To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency AnaemiaCompletedNCT03591406Phase 3Results posted
• HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B PatientsCompletedNCT03569891Phase 3Results posted
• Dose Confirmation Trial of AAV5-hFIXco-PaduaCompletedNCT03489291Phase 2Results posted
• Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeCompletedNCT03473223Phase 3Results posted
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly AdultsCompletedNCT03314662Phase 3Results posted
• Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsTerminatedNCT03221842Phase 3Results posted
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of AgeCompletedNCT03165617Phase 3Results posted
• Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and HyperkalemiaTerminatedNCT03087058Phase 2Results posted
• Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney DiseaseCompletedNCT03071263Phase 2Results posted
• Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)CompletedNCT03033745Phase 4Results posted
• Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron DeficiencyCompletedNCT02937454Phase 4Results posted
• A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.CompletedNCT02914275Phase 3Results posted
• A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgeCompletedNCT02839330Phase 3Results posted
• A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial InfarctionCompletedNCT02742103Phase 2Results posted
• Patiromer With or Without Food for the Treatment of HyperkalemiaCompletedNCT02694744Phase 4Results posted
• A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With HyperphosphataemiaTerminatedNCT02688764Phase 3Results posted
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of AgeCompletedNCT02587221Phase 3Results posted
• Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)CompletedNCT02583256Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of AgeCompletedNCT02545543Phase 3Results posted
• Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia BCompletedNCT02396342Phase 1/2Results posted
• A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT02316353Phase 3Results posted
• Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05CompletedNCT02255409Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.CompletedNCT02214225Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 YearsCompletedNCT02212106Phase 4Results posted
• An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia ACompletedNCT02172950Phase 3Results posted
• A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.CompletedNCT02108262Phase 2Results posted
• Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia ACompletedNCT02093897Phase 3Results posted
• A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCompletedNCT02053792Phase 3Results posted
• Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months OldCompletedNCT02035696Phase 1/2Results posted
• An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on HemodialysisTerminatedNCT02033317Phase 2Results posted
• Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT02027701Phase 3Results posted
• Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid ArthritisCompletedNCT02015520Phase 2Results posted
• Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.CompletedNCT01964989Phase 3Results posted
• A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT01912456Phase 3Results posted
• A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01863433Phase 4Results posted
• A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01857297Phase 4Results posted
• A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)CompletedNCT01810939Phase 3Results posted
• Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 InfectionCompletedNCT01734850Phase 1/2Results posted
• A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia BCompletedNCT01662531Phase 3Results posted
• A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01591837Phase 4Results posted
• A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous RouteCompletedNCT01576523Phase 1/2Results posted
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)CompletedNCT01545076Phase 3Results posted
• Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's DiseaseTerminatedNCT01545050Phase 2Results posted
• Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)TerminatedNCT01530256Phase 1/2Results posted
• A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BCompletedNCT01496274Phase 2/3Results posted
• Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) TherapyCompletedNCT01490450Phase 2Results posted
• An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia ACompletedNCT01486927Phase 2/3Results posted
• Postmarketing Immunogenicity Study in HAE Subjects Treated With BerinertCompletedNCT01467947Phase 4Results posted
• A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis PatientsCompletedNCT01464190Phase 3Results posted
• Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01458171Phase 3Results posted
• Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer SubjectsTerminatedNCT01403064Phase 2Results posted
• A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT01390649Phase 4Results posted
• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to MethotrexateCompletedNCT01373151Phase 2Results posted
• Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)CompletedNCT01371747Phase 2Results posted
• A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia BCompletedNCT01361126Phase 1/2Results posted

← CSL Limited overview and focus areas